TY - JOUR
T1 - Mesenchymal Stem Cells in Fibrotic Disease
AU - El Agha, Elie
AU - Kramann, Rafael
AU - Schneider, Rebekka K.
AU - Li, Xiaokun
AU - Seeger, Werner
AU - Humphreys, Benjamin D.
AU - Bellusci, Saverio
N1 - Funding Information:
E.E.A. was supported by a start-up grant from the Excellence Cluster Cardio-Pulmonary System (ECCPS) . E.E.A. also acknowledges the support of the Universitätsklinikum Gießen und Marburg (UKGM) and the German Center for Lung Research (DZL) . S.B. was supported by the German Research Foundation ( DFG ; BE4443/4-1 , BE4443/6-1 , KFO 309 , and CRC1213 ), Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) , UKGM , Universities of Giessen and Marburg Lung Center (UGMLC) , DZL , COST ( BM1201 ) and NIH/NHLBI ( 1R01HL086322-01A2 and HL107307 ). R.K.S. was supported by grants from the DFG ( SCHN 1188/5-1 ) and Interdisciplinary Center for Clinical Research (IZKF) RWTH Aachen ( O1-5 ) and a clinical research grant from the European Hematology Association (EHA) . R.K. was supported by grants from the DFG ( KR-4073/3-1 , SFBTRR57 , SCHN 1188/5-1 ) and the European Research Council ( ERC-StG 677448 ), a START grant from the RWTH Aachen University ( 101/15 ), and a grant from the State of North Rhine-Westphalia ( Return to NRW) . B.D.H. was supported by the NIH/NIDDK ( DK088923 , DK103740 , and DK103050 ) and by an Established Investigator Award of the American Heart Association ( EIA14650059 ). Due to space limitations, we could not cover all the works done on this topic by all of our colleagues.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/8/3
Y1 - 2017/8/3
N2 - Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation. Investigating the cellular origin of myofibroblasts in various diseases is thus a promising strategy for developing targeted anti-fibrotic treatments. Recent studies using genetic lineage tracing technology have implicated diverse organ-resident perivascular mesenchymal stem cell (MSC)-like cells and bone marrow-MSCs in myofibroblast generation during fibrosis development. In this Review, we give an overview of the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow. Fibrosis is associated with organ failure and is characterized by aberrant myofibroblast accumulation; thus, investigating the cellular origin of myofibroblasts is a promising therapeutic strategy. Here we discuss the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.
AB - Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation. Investigating the cellular origin of myofibroblasts in various diseases is thus a promising strategy for developing targeted anti-fibrotic treatments. Recent studies using genetic lineage tracing technology have implicated diverse organ-resident perivascular mesenchymal stem cell (MSC)-like cells and bone marrow-MSCs in myofibroblast generation during fibrosis development. In this Review, we give an overview of the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow. Fibrosis is associated with organ failure and is characterized by aberrant myofibroblast accumulation; thus, investigating the cellular origin of myofibroblasts is a promising therapeutic strategy. Here we discuss the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.
KW - lineage tracing
KW - mesenchymal stem cells
KW - organ fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85030481526&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2017.07.011
DO - 10.1016/j.stem.2017.07.011
M3 - Review article
C2 - 28777943
AN - SCOPUS:85030481526
VL - 21
SP - 166
EP - 177
JO - Cell Stem Cell
JF - Cell Stem Cell
SN - 1934-5909
IS - 2
ER -